10 Νοε 2026
An important milestone for the iPROLEPSIS project
On 9 November 2026, the iPROLEPSIS project reached an important milestone with the enrolment of the first participant in the Prevention of PsA inflammation through digital care: an intervention study (iPROLEPSIS-PPIDC).
The study aims to provide a personalised approach to dealing with the triggers of stress, mechanical stress and changes in the microbiome, using findings from the iPROLEPSIS digital biomarker work and the PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID).
In people with psoriatic arthritis and low disease activity, a personalised intervention on food, physical activity and stress, based on a personal profile of stress, mechanical stress and microbiome, will be compared with usual care.
The study will also evaluate the take-up and acceptability of the digital biomarker and intervention as part of normal medical treatment among patients, doctors and nurses, and assess compliance with the personalised intervention.
The enrolment of the first participant marks an important step in the implementation of the iPROLEPSIS-PPIDC study.
Read more about the iPROLEPSIS clinical studies: https://www.iprolepsis.eu/clinical-studies
